Focus: AnaptysBio is a San Diego-based public biotechnology company focused on antibody therapeutics for oncology and inflammatory diseases. The company is in early-stage development with a pre-commercial pipeline and minimal revenue generation.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow AnaptysBio to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for AnaptysBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AnaptysBio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
+1 more
ANABV Price Today: AnaptysBio, Inc. Stock Price, Quote & Chart - MEXC
ANABV Price Today: AnaptysBio, Inc. Stock Price, Quote & Chart MEXC
ANABV Price Today: AnaptysBio, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
ANABV Price Today: AnaptysBio, Inc. Stock Price, Quote & Chart | MEXC MEXC Exchange
Spin-off Imminent At AnaptysBio - San Diego Business Journal
Spin-off Imminent At AnaptysBio San Diego Business Journal
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) The Globe and Mail
8-K Filing: First Tracks Biotherapeutics, Inc. (TRAX) (CIK 0002091349) — EX-99.1
EX-99.1
8-K Filing: ALUMIS INC. (ALMS) (CIK 0001847367) — EXHIBIT 99.2
EXHIBIT 99.2
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Corporate restructuring risk is elevated; job security for new hires is uncertain pending spin-off clarity.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo